Nov 2, 2021
AARP CEO Jo Ann Jenkins issued the following statement reacting to the announcement of a deal to lower prescription drug costs
Oct 28, 2021AARP Statement: We Are Outraged that Build Back Better Framework Fails to Lower Price of Prescription Drugs
AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy A. LeaMond issued the following statement reacting to the Build Back Better framework’s failure to lower prescription drug prices.
Oct 27, 2021New Report Highlights Innovative and Pioneering Practices for Supporting a Healthy Aging Population Worldwide2021 AARP Global Conference Focuses on New Ways to Live and Age
A new Aging Readiness and Competitiveness report from AARP and Economist Impact shows that while global life expectancy is increasing, there is a growing gap worldwide between how long someone will live and how many healthy years of life they can expect. This gap was only exacerbated as a result of the coronavirus pandemic, which disproportionately affected older adults.
Sep 28, 2021AARP Report: Average Specialty Drug Price Reached $84,442 in 2020, Rising More Than Three Times Faster Than the Prices of Other Goods and ServicesAARP Is Urging Congress to Pass Prescription Drug Reform This Year
Retail prices for 180 widely used specialty prescription drugs increased by an average of 4.8% in 2020, more than three times the rate of general inflation for that same period (1.3%), according to AARP’s latest Rx Price Watch Report.
Sep 17, 2021
AARP has launched a full-scale campaign, including a $4 million ad buy, pushing back on false claims from the pharmaceutical industry that reforms would limit Americans’ access to medicines. AARP has called for fair drug prices for years and is urging Congress to pass legislation that would allow Medicare to negotiate drug prices, put a cap on out-of-pocket costs that older adults pay for their prescription drugs and impose penalties on drug companies that raise prices faster than the rate of inflation.